The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lower-dose versus standard-dose abiraterone in patients with metastatic castration resistant prostate cancer: A multicentric randomized phase III non-inferiority trial.
 
Minit Shah
No Relationships to Disclose
 
Vanita Noronha
Research Funding - AstraZeneca (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Roche India (Inst)
Travel, Accommodations, Expenses - American Society of Clinical Oncology
 
Nandini Menon
No Relationships to Disclose
 
Vijay Patil
Research Funding - AstraZeneca (Inst); Eisai Germany (Inst); Intas (Inst); Johnson & Johnson/Janssen (Inst); NATCO Pharma (Inst); Novartis (Inst)
 
Akhil Kapoor
Research Funding - AstraZeneca (Inst); Bayer (Inst); Biocon (Inst); Lilly (Inst); Novartis (Inst)
 
Amrit Dhar
No Relationships to Disclose
 
Supriya Goud
No Relationships to Disclose
 
Archi Agrawal
No Relationships to Disclose
 
Nilesh Sable
No Relationships to Disclose
 
Nitesh Chavan
No Relationships to Disclose
 
Anupama Pradosh
No Relationships to Disclose
 
Vikram Gota
No Relationships to Disclose
 
Kumar Prabhash
Research Funding - Alkem Laboratories (Inst); Aurigene Oncology Limited (Inst); BDR Pharmaceutics (Inst); Biocon (Inst); Dr. Reddy's Laboratories (Inst); Fresenius Kabi (Inst); Johnson and Johnson (Inst); NATCO Pharma (Inst); Roche (Inst)